Revenue Update on Xtant Medical Holdings Inc(NYSEMKT:XTNT)

Xtant Medical Holdings Inc(NYSEMKT:XTNT) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 1, 2016. Company reported revenue of $21.46M. Analysts estimated a revenue of $21.59M. Earnings per share were $-0.37. Analysts had estimated an EPS of $-0.40.

Several Insider Transactions has been reported to the SEC. On May 10, 2016, Daniel S Goldberger (CEO) purchased 5,000 shares at $2.34 per share price.Also, On Dec 3, 2015, Kent L Swanson (director) purchased 3,300 shares at $2.83 per share price.On Nov 23, 2015, David Louis Kirschman (director officer 10% owner (EVP & Chief Scientifi) purchased 2,000 shares at $2.99 per share price, according to the Form-4 filing with the securities and exchange commission.

Bacterin International Holdings Inc. is engaged in developing manufacturing and marketing biologics products to domestic and international markets. The Company’s bone graft products are used in a range of applications including enhancing fusion in spine surgery relief of back pain through facet joint stabilization promotion of bone growth in foot and ankle surgery promotion of skull healing following neurosurgery and subchondral bone repair in knee and other joint surgeries. The Company’s acellular dermis scaffolds are utilized in wound care and plastic and reconstructive procedures. The Company also develops custom surgical instruments for use with its allografts. The Company’s products include OsteoSponge OsteoSponge SC OsteoSelect DBM putty OsteoWrap OsteoLock BacFast HD OsteoSTX hMatrix and its line of 3Demin products as well as other allograft products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Xtant Medical Holdings Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Xtant Medical Holdings Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.